Français

The Maritimes includes New Brunswick, Nova Scotia and Prince Edward Island!


Here in the Maritimes, we have an incredible community of volunteers, donors and sponsors, as well as an innovative team of researchers and healthcare professionals. These people are the heart and soul of our organization, and there are so many exciting ways to get involved! Every volunteer, donor, researcher and sponsor helps us to improve the lives of those affected by Crohn’s disease and ulcerative colitis, and brings us closer to finding cures.

Director, Community Fundraising Events and Campaigns
Rachel Narcis

416-920-5035 | 1-800-387-1479

Events

People in front of a speaker

Gutsy Learning Series: IBD and your diagnostics

Join Dr. Seth Shaffer, gastroenterologist and Assistant Professor of Medicine at the University of Manitoba, for an informative session on the key diagnostic tests used in identifying and managing IBD ...

 • 
Virtual
 • 
Older couple sitting a table with tablet

Caregiver Group Peer Support Event

Ready to connect with those who understand the challenges of being a caregiver to someone with Crohn's disease, ulcerative colitis, and other forms of inflammatory bowel disease (IBD)?   ...

 • 
Virtual
 • 
Woman sitting on a couch smiling while looking at her laptop

Canada Wide Peer Connect Event

Ready to connect with those who understand the challenges of Crohn’s disease, ulcerative colitis, and other forms of inflammatory bowel disease (IBD)?   Join our upcoming Peer Connect ...

 • 
Virtual
 • 
Remember to bookmark this page.

Crohn’s and Colitis Canada – Maritimes Region mailing address

PO Box 59
Waterville, NS B0P 1V0

(902) 210-4554 or 1-800-265-1101

Search by Postal Code

News

The Canadian Inflammatory Bowel Disease Research Consortium awards first $1M Pioneer Grant from Takeda Canada

The Canadian Inflammatory Bowel Disease Research Consortium awards first $1M Pioneer Grant from Takeda Canada

Crohn’s and Colitis Canada and Pfizer Canada Announce 2022 Women in IBD Award Recipients

Crohn’s and Colitis Canada and Pfizer Canada Announce 2022 Women in IBD Award Recipients

Health Canada has approved SKYRIZI® (risankizumab) an intravenous and subcutaneous medication treatment for adults with moderately to severely active Crohn's Disease

Health Canada has approved SKYRIZI® (risankizumab) an intravenous and subcutaneous medication treatment for adults with moderately to severely active Crohn's Disease

 15 16 17 18 19 20 21 22 23 24